This summer, Todd Hagopian and Jason Spatafora told us that traditional Biotech companies are looking at Cannabis-based Biotech stocks as buyout candidates. Since then, the four stocks they recommended are up on average 20%, while the S&P 500 is up less than 2%. We welcome them again to discuss the election and the prospects for the Marijuana stock sector.
Todd Hagopian and....More>>>
Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump....More>>>
Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in....More>>>
Today I want to pull back the curtain and explain how I use a little known Federal Drug Administration secret to identify the best biotech stocks that could trigger big profits in months.
One that tells me exactly when drug companies expect to receive approval from the FDA.
This information is an incredibly valuable first step when I begin researching a biotech stock.
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Pfizer gets deep with its PARP inhibitor
Company: Pfizer (PFE)
Therapy: Talazoparib, an inhibitor of PARP
Disease: Advanced breast cancer
News: PFE presented....More>>>